共 222 条
[1]
Foulkes WD(2010)Triple-negative breast cancer N Engl J Med 363 1938-1948
[2]
Smith IE(2021)Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline J Clin Oncol 39 1485-1505
[3]
Reis-Filho JS(2018)Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis Ann Oncol 29 1497-1508
[4]
Korde LA(2021)Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis BMJ 375 e066381-654
[5]
Somerfield MR(2015)Evolving treatment strategies for triple-negative breast cancer J Natl Compr Canc Netw 13 652-5829
[6]
Carey LA(2018)Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel Clin Cancer Res 24 5820-821
[7]
Crews JR(2020)Pembrolizumab for early triple-negative breast cancer N Engl J Med 382 810-567
[8]
Denduluri N(2022)Event-free survival with pembrolizumab in early triple-negative breast cancer N Engl J Med 386 556-684
[9]
Hwang ES(2020)Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial JAMA Oncol 6 676-543
[10]
Poggio F(2022)Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study Ann Oncol 33 534-5461